Exelixis, Inc.

Informe acción NasdaqGS:EXEL

Capitalización de mercado: US$9.7b

Exelixis Dirección

Dirección controles de criterios 4/4

El CEO de Exelixis es Mike Morrissey , nombrado en Jul 2010, tiene una permanencia de 14.33 años. compensación anual total es $16.42M, compuesta por 7.3% salario y 92.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.55% de las acciones de la empresa, por valor de $53.17M. La antigüedad media del equipo directivo y de la junta directiva es de 8.5 años y 7.4 años, respectivamente.

Información clave

Mike Morrissey

Chief Executive Officer (CEO)

US$16.4m

Compensación total

Porcentaje del salario del CEO7.3%
Permanencia del CEO14.3yrs
Participación del CEO0.5%
Permanencia media de la dirección8.5yrs
Promedio de permanencia en la Junta Directiva7.4yrs

Actualizaciones recientes de la dirección

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Oct 26
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30
An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Morrissey en comparación con los beneficios de Exelixis?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

US$467m

Jun 30 2024n/an/a

US$350m

Mar 31 2024n/an/a

US$205m

Dec 31 2023n/an/a

US$208m

Sep 30 2023n/an/a

US$92m

Jun 30 2023n/an/a

US$164m

Mar 31 2023n/an/a

US$154m

Dec 31 2022US$17mUS$1m

US$182m

Sep 30 2022n/an/a

US$308m

Jun 30 2022n/an/a

US$273m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$8mUS$1m

US$231m

Sep 30 2021n/an/a

US$164m

Jun 30 2021n/an/a

US$94m

Mar 31 2021n/an/a

US$65m

Dec 31 2020n/an/a

US$112m

Sep 30 2020n/an/a

US$152m

Jun 30 2020n/an/a

US$282m

Mar 31 2020n/an/a

US$294m

Dec 31 2019n/an/a

US$321m

Sep 30 2019n/an/a

US$612m

Jun 30 2019n/an/a

US$642m

Mar 31 2019n/an/a

US$650m

Dec 31 2018n/an/a

US$690m

Sep 30 2018n/an/a

US$368m

Jun 30 2018n/an/a

US$323m

Mar 31 2018n/an/a

US$253m

Dec 31 2017n/an/a

US$154m

Compensación vs. Mercado: La compensación total ($USD16.42M) de Mike está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD12.87M).

Compensación vs. Ingresos: La compensación de Mike ha sido consistente con los resultados de la empresa en el último año.


CEO

Mike Morrissey (63 yo)

14.3yrs

Permanencia

US$16,423,307

Compensación

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Stelios Papadopoulos
Co-Founder & Chair of the Board29.9yrsUS$519.97k0.43%
$ 42.3m
Michael Morrissey
CEO, President & Director14.3yrsUS$16.42m0.55%
$ 53.2m
Christopher Senner
Executive VP & CFO9.3yrsUS$4.95m0.16%
$ 15.4m
Dana Aftab
Executive VP of Discovery and Translational Research & Chief Scientific Officer1.9yrsUS$5.65m0.076%
$ 7.4m
Jeffrey Hessekiel
Executive VP & General Counsel10.8yrsUS$4.56m0.12%
$ 11.8m
Amy Peterson
Executive VP1.3yrsUS$7.38msin datos
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations7.9yrssin datossin datos
Tony Redmond
Senior Vice President of Human Resourcesless than a yearsin datossin datos
Anne Champsaur
Senior Vice President of Drug Safety9.6yrssin datossin datos
William Berg
Senior Vice President of Medical Affairs9.2yrssin datossin datos
Patrick Haley
Executive Vice President of Commercial7.9yrsUS$4.65m0.049%
$ 4.8m
Stefan Krauss
VP & Head of Business Developmentno datasin datossin datos

8.5yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EXEL es experimentado (8.5 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Stelios Papadopoulos
Co-Founder & Chair of the Board29.9yrsUS$519.97k0.43%
$ 42.3m
Michael Morrissey
CEO, President & Director14.3yrsUS$16.42m0.55%
$ 53.2m
Jack Wyszomierski
Independent Director20.8yrsUS$490.97k0.12%
$ 11.3m
George Poste
Independent Director20.3yrsUS$482.22k0.063%
$ 6.1m
Charles Sawyers
Member of the Scientific Advisory Boardno datasin datossin datos
Ronald Evans
Member of the Scientific Advisory Boardno datasin datossin datos
Sue Eckhardt
Independent Directorless than a yearsin datos0%
$ 0
Mary Beckerle
Independent Directorless than a yearsin datos0%
$ 0
Julie Smith
Independent Director8.2yrsUS$490.92k0.00027%
$ 26.3k
Maria Freire
Independent Director6.6yrsUS$488.72k0.025%
$ 2.5m
Robert Oliver
Independent Director1.5yrsUS$717.44k0.0016%
$ 154.9k
Tomas Heyman
Independent Director1.5yrsUS$716.19k0.0016%
$ 154.9k

7.4yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de EXEL se considera experimentada (7.4 años de antigüedad promedio).